Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.85 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | GLA | P06280 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | STAT6 | P42226 | 1/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cositecan SCHEMBL29378211 | 1.00 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| Cositecan SCHEMBL15692672 | 1.00 | TOP1 (0.85) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL15419296 | 0.94 | TOP1 (0.83) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL3152675 | 0.94 | TOP1 (0.83) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL4453581 | 0.93 | TOP1 (0.90) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL3150912 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL27606708 | 0.92 | TOP1 (0.86) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL11070279 | 0.92 | TOP1 (0.86) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL3150335 | 0.92 | TOP1 (0.80) | TOP1MEN1KMT2AALDH1A1GLA | |
| SCHEMBL3154899 | 0.92 | TOP1 (0.80) | TOP1MEN1KMT2AALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090139-A1 | ANTI-LY6K ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NORMUNITY, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4605014-A1 | NOVEL ANTI-TPBG ANTIBODY AND ANTIBODY-DRUG-CONJUGATES BASED THEREON, THERAPEUTIC METHODS AND USES THEREOF | Tubulis GmbH (DE) | 2025-08-27 | — | — | EP | claimed |
| EP-4605013-A1 | NOVEL ANTIBODY DRUG CONJUGATES WITH NOVEL NAPI2B ANTIBODIES, THERAPEUTIC METHODS AND USES THEREOF | Tubulis GmbH (DE) | 2025-08-27 | — | — | EP | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| EP-4588485-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-23 | — | — | EP | claimed |
| EP-4584256-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2025-07-16 | — | — | EP | claimed |
| US-20250205353-A1 | Antibody-conjugates for targeting of tumours expressing nectin-4 | SYNAFFIX B.V. (NL) | 2025-06-26 | — | — | US | claimed |
| WO-2025088200-A2 | ACID PHOSPHATASE 3 LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-05-01 | — | — | WO | claimed |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2022-06-02 | — | — | US | claimed |
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-05-26 | — | — | US | claimed |
| EP-3997093-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114341162-A | Peptide conjugates of cytotoxins as therapeutic agents | 赛博克萨2公司 | 2022-04-12 | — | — | CN | claimed |
| EP-3952917-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-02-16 | — | — | EP | claimed |
| US-8569265-B2 | Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3′, 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-20120282261-A1 | Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof | BIONUMERIK PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | claimed |
| EP-1694242-A1 | PHARMACEUTICAL FORMULATIONS OF CAMPTOTHECINS AND PROCESS FOR MAKING SAME | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | claimed |
| US-20060094692-A1 | Pharmaceutical formulations of camptothecins and process for making same | BIONUMERIK PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
| WO-2005060871-A1 | PHARMACEUTICAL FORMULATIONS OF CAMPTOTHECINS AND PROCESS FOR MAKING SAME | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, NCL, PBRM1 | TOP1 75/4885MEN1 94/4885KMT2A 2171/4885 |
| US-20250205353-A1 | Antibody-conjugates for targeting of tumours expressing nectin-4 | NECTIN4, HEXD, CD22 | TOP1 3596/4885MEN1 623/4885KMT2A 960/4885 |
| US-20120282261-A1 | Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof | KPNA4, KPNA1, KPNA3 | TOP1 31/4885MEN1 875/4885KMT2A 55/4885 |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | TOP1 226/4885MEN1 191/4885KMT2A 1880/4885 |
| US-20060094692-A1 | Pharmaceutical formulations of camptothecins and process for making same | LPXN, CGAS, PDE11A | TOP1 10/4885MEN1 141/4885KMT2A 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.